ATS (ATS) Jefferies Global Industrial Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Industrial Conference summary
22 Jan, 2026Business overview and market focus
Operates as a decentralized technology and solutions provider, serving markets such as life sciences, regulated food, nuclear, EV, and consumer products.
Supports customers from prototype to mass production, designing and building equipment and providing ongoing service.
Largest market is life sciences, with significant presence in energy (mainly nuclear), food and beverage, and consumer products.
Recurring revenue represents 25–35% of business, with a focus on expanding this share.
Shifted from highly customized integration to a more balanced mix, with standard products now about 30% of business.
Financial performance and growth strategy
Achieved CAD 3.3 billion in revenue, with a five-year CAGR over 19% and adjusted EBITDA above 15%.
Focuses on profitable growth, margin expansion, and recurring revenue.
Operates in over 65 facilities and 85 offices across 20+ countries, employing more than 7,000 people.
Leverages acquisitions for growth, completing over 25 in the last five years.
Targets double-digit ROIC within five years for acquisitions, often achieving this in less than three for smaller deals.
Operational excellence and business model
Uses the ATS Business Model (ABM) for continuous improvement, focusing on people, process, and performance.
Measures key metrics: bookings, revenue, margin expansion, working capital, on-time delivery, quality, and internal fill rate.
Maintains global turnover below 5% and high employee engagement through empowerment and leadership development.
Integrates acquisitions with a structured playbook and ABM boot camp for leaders.
Applies supply chain leverage to quickly improve margins in acquired businesses.
Latest events from ATS
- Margin expansion, portfolio diversification, and disciplined M&A drive future growth plans.ATS
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Q3 revenue up 16.7%, net income surges, and strong backlog supports future growth.ATS
Q3 20264 Feb 2026 - Life sciences and nuclear energy drive growth, with disciplined M&A and resilient market focus.ATS
Raymond James 46th Annual Institutional Investors Conference3 Feb 2026 - Order bookings surged 18.4% as life sciences growth offset transportation softness.ATS
Q1 20252 Feb 2026 - Tripled revenue, tech innovation, and services expansion drive growth in life sciences and EV.ATS
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Strategic focus on regulated markets, M&A, and technology drives growth and innovation.ATS
15th Annual Global Materials & Industrials Conference31 Jan 2026 - Q2 revenue fell 17% as life sciences bookings hit a record, offsetting transportation weakness.ATS
Q2 202516 Jan 2026 - Life sciences and food lead growth as margin targets and innovation remain central priorities.ATS
Scotiabank Transportation & Industrials Conference14 Jan 2026 - High-value automation in life sciences and food safety drives growth and margin expansion.ATS
UBS Global Industrials and Transportation Conference12 Jan 2026